

Electronic Supplementary Information

**Amyloidogenesis highlighted by designed peptides forming supramolecular  
self-assemblies**

M. Ouberaï, G. T. Dolphin, P. Dumy, and J. Garcia\*

*Département de Chimie Moléculaire, UMR-CNRS 5250, ICMG FR 2607,  
Université Joseph Fourier, BP53, 38041 Grenoble Cedex 9, France*

E-mail: [julian.garcia@ujf-grenoble.fr](mailto:julian.garcia@ujf-grenoble.fr)

**Table of Contents:**

<b>Synthesis and Experimental Section.....</b>	<b>- 2 -</b>
<b>HPLC profiles and SM spectra.....</b>	<b>- 5 -</b>
<b>Kinetics data.....</b>	<b>- 8 -</b>




Figure S1. Chemical structures of peptide edifices and corresponding precursors.

**Synthesis of cyclic decapeptide 3** (Figure S2). The linear peptide R(Pmc)-K(Dde)-R(Pmc)-P-G-R(Pmc)-K(Dde)-R(Pmc)-P-G was first built up automatically (Advance Chem Tech 348  $\Omega$  peptide synthesizer) on Fmoc-Gly-Sasrin<sup>®</sup> resin (500 mg, 0.69 mmol.g<sup>-1</sup>) and cyclized (415

mg,  $1.59 \cdot 10^{-4}$  mol) in DMF ( $0.5 \text{ mol} \cdot \text{L}^{-1}$ ) under high dilution using PyBOP (1.2 eq.) and DIPEA. The white solid powder obtained after precipitation and washing in diethyl ether was solubilized in a solution of 2% of hydrazine in DMF to remove Dde protecting groups. The cyclopeptidic intermediate **1** ( $272 \text{ mg}$ ,  $1.21 \cdot 10^{-4}$  mol) was then obtained after precipitation and washing in diethyl ether (76% yield from the linear peptide). To a solution of compound **1** ( $272 \text{ mg}$ ,  $1.21 \cdot 10^{-4}$  mol) in DMF ( $0.01 \text{ mol} \cdot \text{L}^{-1}$ ), were added Boc-Ser(*t*Bu)-OH (3 eq), PyBOP (3 eq.) and DIPEA. The mixture was stirred for 2 h at r.t. Then Boc, *t*Bu and Pmc protecting groups were removed using a solution of TFA/TIS/H<sub>2</sub>O (95:2.5:2.5) ( $0.01 \text{ mol} \cdot \text{L}^{-1}$ ). After 2 h, the solvent was evaporated and the crude compound **2** ( $145 \text{ mg}$ ,  $7.08 \cdot 10^{-5}$  mol) was obtained by precipitation with diethyl ether as white solid powder with 59% yield. HPLC  $t_R = 4.9 \text{ min}$ . ESI-MS calc 1362.8, found 1362.5.

To a solution of compound **2** ( $5 \text{ mg}$ ,  $2.44 \cdot 10^{-6}$  mol) in H<sub>2</sub>O/CH<sub>3</sub>CN (1:1) ( $0.01 \text{ mol} \cdot \text{L}^{-1}$ ) was added NaIO<sub>4</sub> (20 eq.). The reaction was stirred for 20 min at r.t. and immediately purified by RP-HPLC (C18 Nucleosil<sup>®</sup> column, 5-100% B in 30 min). This procedure was realized 8 times to afford compound **3** ( $21 \text{ mg}$ ,  $1.19 \cdot 10^{-5}$  mol) as a white powder with 61% yield. HPLC  $t_R = 5.0 \text{ min}$ . ESI-MS calc 1300.7, found 1300.4.




Figure S2. Synthesis of the cyclodecapeptide **3**. (a) Piperidine/DMF (1:4); (b) Fmoc-Xaa-OH (2 eq.), PyBOP (2 eq.), DIPEA (3-4 eq.), DMF; (c) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:99), 10 min (three times); (d) PyBOP (1.2 eq.), DIPEA (3-4 eq.), DMF ( $0.5 \cdot 10^{-3} \text{ M}$ ), 1 h; (e) Hydrazine/DMF (2:98), 2 h, 76% from the linear form of **1**; (f) i) Boc-Ser(*t*Bu)-OH (3 eq.), PyBOP (3 eq.), DIPEA, DMF ( $10^{-2} \text{ M}$ ), 2 h; ii) TFA/TIS/H<sub>2</sub>O (95:2.5:2.5), 2 h, 59% from **1** (2 steps); (g) NaIO<sub>4</sub> (20 eq.), H<sub>2</sub>O/CH<sub>3</sub>CN (1:1), 61%.

**Synthesis of peptide 4** (Figure S3). The GGCA $\beta_{16-37}$ Y<sub>20</sub>K<sub>22</sub>K<sub>24</sub>C peptide sequence was synthesized automatically (Applied Biosystems) by solid phase synthesis on NovaSyn<sup>®</sup> TG Sieber resin ( $300 \text{ mg}$ ,  $0.19 \text{ mmol} \cdot \text{g}^{-1}$ ). Peptide on resin ( $5.70 \cdot 10^{-5}$  mol) was then solvated in 10 mL of DMF and the pH was adjusted with DIEPA to pH 8-9. 2-(1-ethoxyethylideneaminoxy)acetic acid (2 eq.), and PyBOP (2 eq.) were added to the resin

solution. The mixture was stirred for 1 h at r.t. Peptide was then solvated in DMF and iodine (20 eq.) was added. The peptide was released from the resin using 10 mL cleavage solution of TFA/H<sub>2</sub>O/TIS (95:2.5:2.5). The mixture was stirred for 2 h at r.t then 10 eq. of NH<sub>4</sub>I was added and the mixture was stirred for another 30 min. The crude free peptide **4** was obtained as a white powder (142 mg, 4.34.10<sup>-5</sup> mol) and then purified by RP-HPLC (C18 Nucleosil<sup>®</sup> column, 5-100% B in 30 min) affording pure peptide **4** (15.1 mg, 4.62.10<sup>-6</sup> mol) as a white powder with 8% overall yield from the resin. HPLC t<sub>R</sub> = 8.3 min. ESI-MS calc 2698.4, found 2699.1.





Figure S3. Synthesis of the peptide **4**. (a) Piperidine/NMP (1:4); (b) Fmoc-Xaa-OH (10 eq.), HBTU (10 eq.), DIPEA (20 eq.), NMP; (c) 2-(1-ethoxyethylideneamino)oxy)acetic acid (2 eq.), PyBOP (2 eq.), DIPEA (3-4 eq.), DMF; (d) I<sub>2</sub> (20 eq.), DMF; (e) TFA/H<sub>2</sub>O/TIS (95:2.5:2.5), NH<sub>4</sub>I (10 eq.), 8% from the resin.

The cyclic decapeptide **5** and the peptide **6** (Figure S1) were synthesized as previously described.<sup>1</sup> Synthetic A $\beta$ <sub>1-40</sub> was prepared as previously described.<sup>2</sup>




Figure S4. Characterization of compound **2Lin** by chromatography and mass spectrometry. RP-HPLC profile (a); ESI-MS analysis (b).




Figure S5. Characterization of compound **2Loop** by chromatography and mass spectrometry. RP-HPLC profile (a); ESI-MS analysis (b).





Figure S6. Characterization of compound **4Loop** by chromatography and mass spectrometry. RP-HPLC profile (a); ESI-MS analysis (b).

**Kinetics studies.** A concentration 25  $\mu\text{M}$  of **4Loop**, **2Loop** and **2Lin** and 6  $\mu\text{M}$  of **4Lin** were used for kinetic studies at 20°C. Fibril formation was monitored by the binding of Thioflavin T (10  $\mu\text{M}$ ), studying the fluorescence at 480 nm with excitation at 440 nm. The kinetic constants  $k_1$  and  $k_2$  were obtained using the Finke-Watzky (F-W) two-step mechanism of nucleation followed by autocatalytic surface growth.



Using this mechanism (where A is the initial monomer and B (catalytic) aggregated form of peptide edifices past the critical nucleus size) we can extract from experimental data, two constants,  $k_1$ , which represents the nucleation process and  $k_2$ , which represents the extension of the fibre (Table S1). This model can be mathematically translated by the following equations:

$$[A]_t = \frac{\frac{k_1}{k_2} + [A]_0}{1 + \frac{k_1}{k_2} \cdot [A]_0 \cdot \exp(k_1 + k_2 \cdot [A]_0) \cdot t}$$

or

$$[B]_t = [A]_0 - \frac{\frac{k_1}{k_2} + [A]_0}{1 + \frac{k_1}{k_2} \cdot [A]_0 \cdot \exp(k_1 + k_2 \cdot [A]_0) \cdot t}$$

	<b>4Lin</b>	<b>4Loop</b>	<b>2Loop</b>	<b>2Lin</b>
<b><math>k_1</math> (<math>\text{min}^{-1}</math>)</b>	$160 \times 10^{-3} \pm 2 \times 10^{-2}$	$28 \times 10^{-3} \pm 4 \times 10^{-3}$	$28 \times 10^{-3} \pm 4 \times 10^{-3}$	$2.3 \times 10^{-3} \pm 4 \times 10^{-4}$
<b><math>k_2</math> (<math>\mu\text{M}^{-1} \cdot \text{min}^{-1}</math>)</b>	$46 \times 10^{-3} \pm 5 \times 10^{-3}$	$6.1 \times 10^{-3} \pm 7 \times 10^{-4}$	$3.2 \times 10^{-3} \pm 4 \times 10^{-4}$	$3.6 \times 10^{-3} \pm 4 \times 10^{-4}$
<b><math>t_{1/2}</math> (min)</b>	2.5	8.5	12.6	270.2

Table S1. Rate constants and half-life time values from fitting kinetic data with the F-W two-step mechanism.

1. G. T. Dolphin, P. Dumy and J. Garcia, *Angew. Chem.-Int. Edit.*, 2006, **45**, 2699-2702.
2. G. T. Dolphin, M. Ouberai, P. Dumy and J. Garcia, *ChemMedChem*, 2007, **2**, 1613-1623.